Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern

The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve p...

Descripción completa

Detalles Bibliográficos
Autores: García-Pérez, Javier, Bermejo, Mercedes, Ramírez-García, Almudena, de la Torre-Tarazona, Humberto Erick, Cascajero Díaz, Almudena, Castillo de la Osa, María, Jiménez Santana, Paloma, Aparicio Gómez, Marta, Calonge, Esther, Sancho-López, Aránzazu, Payares-Herrera, Concepción, Layunta Acero, Rocio, Vicente-Izquierdo, Laura, Avendaño-Solá, Cristina, Alcamí, José, Perez-Olmeda, Mayte, Díez-Fuertes, Francisco
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16083
Acceso en línea:http://hdl.handle.net/20.500.12105/16083
Access Level:acceso abierto
Palabra clave:COVID-19
Humans
2019-nCoV Vaccine mRNA-1273
SARS-CoV-2
mRNA Vaccines
Biological Assay
Vaccination
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
id ES_2f399a04c8e5c76589b4e81abc82e4f4
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/16083
network_acronym_str ES
network_name_str España
repository_id_str
spelling Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concernGarcía-Pérez, JavierBermejo, MercedesRamírez-García, Almudenade la Torre-Tarazona, Humberto ErickCascajero Díaz, AlmudenaCastillo de la Osa, MaríaJiménez Santana, PalomaAparicio Gómez, MartaCalonge, EstherSancho-López, AránzazuPayares-Herrera, ConcepciónLayunta Acero, RocioVicente-Izquierdo, LauraAvendaño-Solá, CristinaAlcamí, JoséPerez-Olmeda, MayteDíez-Fuertes, FranciscoCOVID-19Humans2019-nCoV Vaccine mRNA-1273SARS-CoV-2mRNA VaccinesBiological AssayVaccinationAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, CoronavirusThe humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.WileyInstituto de Salud Carlos IIICentro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)20232023-05-1720232023-03-0120232023-03-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/16083reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/160832026-06-12T12:43:37Z
dc.title.none.fl_str_mv Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
title Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
spellingShingle Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
García-Pérez, Javier
COVID-19
Humans
2019-nCoV Vaccine mRNA-1273
SARS-CoV-2
mRNA Vaccines
Biological Assay
Vaccination
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
title_short Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
title_full Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
title_fullStr Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
title_full_unstemmed Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
title_sort Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern
dc.creator.none.fl_str_mv García-Pérez, Javier
Bermejo, Mercedes
Ramírez-García, Almudena
de la Torre-Tarazona, Humberto Erick
Cascajero Díaz, Almudena
Castillo de la Osa, María
Jiménez Santana, Paloma
Aparicio Gómez, Marta
Calonge, Esther
Sancho-López, Aránzazu
Payares-Herrera, Concepción
Layunta Acero, Rocio
Vicente-Izquierdo, Laura
Avendaño-Solá, Cristina
Alcamí, José
Perez-Olmeda, Mayte
Díez-Fuertes, Francisco
author García-Pérez, Javier
author_facet García-Pérez, Javier
Bermejo, Mercedes
Ramírez-García, Almudena
de la Torre-Tarazona, Humberto Erick
Cascajero Díaz, Almudena
Castillo de la Osa, María
Jiménez Santana, Paloma
Aparicio Gómez, Marta
Calonge, Esther
Sancho-López, Aránzazu
Payares-Herrera, Concepción
Layunta Acero, Rocio
Vicente-Izquierdo, Laura
Avendaño-Solá, Cristina
Alcamí, José
Perez-Olmeda, Mayte
Díez-Fuertes, Francisco
author_role author
author2 Bermejo, Mercedes
Ramírez-García, Almudena
de la Torre-Tarazona, Humberto Erick
Cascajero Díaz, Almudena
Castillo de la Osa, María
Jiménez Santana, Paloma
Aparicio Gómez, Marta
Calonge, Esther
Sancho-López, Aránzazu
Payares-Herrera, Concepción
Layunta Acero, Rocio
Vicente-Izquierdo, Laura
Avendaño-Solá, Cristina
Alcamí, José
Perez-Olmeda, Mayte
Díez-Fuertes, Francisco
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas)
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.subject.none.fl_str_mv COVID-19
Humans
2019-nCoV Vaccine mRNA-1273
SARS-CoV-2
mRNA Vaccines
Biological Assay
Vaccination
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
topic COVID-19
Humans
2019-nCoV Vaccine mRNA-1273
SARS-CoV-2
mRNA Vaccines
Biological Assay
Vaccination
Antibodies, Neutralizing
Antibodies, Viral
Spike Glycoprotein, Coronavirus
description The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern elicited by vaccination was evaluated in COVID-19 recovered individuals (Rec) separated 1-3 months (Rec2m) or 4-12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody-mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS-CoV-2 lentiviral-based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS-CoV-2 spike were lower in naïve participants after two doses than in Rec after a single dose (p < 0.05). After two doses in Rec, levels of total Ig to receptor-binding domain were significantly increased in Rec9m compared to Rec2m (p < 0.001). The neutralizing potency observed in Rec9m was consistently higher than in Rec2m against variants of concern (VOCs) Alpha, Beta, Delta, and BA.1 sublineage of Omicron with 2.2-2.8-fold increases. Increasing the interval between SARS-CoV-2 infection and the vaccination with messenger RNA-based vaccines to more than 3 months generates a more efficient heterologous humoral immune response against VOCs by allowing enough time to mount a strong recall memory B cell response.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023-05-17
2023
2023-03-01
2023
2023-03-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/16083
url http://hdl.handle.net/20.500.12105/16083
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405463743823872
score 15.812455

Similares en LA Referencia